[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:dementia-associated-with-parkinson-s-disease":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":43,"states":44},"Dementia associated with Parkinson's Disease",5,4,[8,16,23,29,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07154511","Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:48.678868Z","2026-05-05T02:43:27.112068Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03143374","PET Tau - Neurodegenerative Disease Imaging",[20],"Phase 2\u002FPhase 3","2026-08-26T02:16:03.788292Z","2026-05-05T02:43:28.343973Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04997642","Parkinson's Disease and Movement Disorders Clinical Database",[],"2026-08-26T02:17:52.450442Z","2026-05-13T02:55:06.278551Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07284290","Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia",[33],"Phase 4","2026-08-26T02:15:41.377360Z","2026-05-05T02:35:31.701867Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT07646652","Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease",[],"NOT_YET_RECRUITING","2026-08-26T02:16:47.762107Z","2026-06-16T05:54:07.903276Z",[],[]]